Filtered By:
Specialty: International Medicine & Public Health
Condition: Bleeding
Drug: Coumadin
This page shows you your search results in order of date.
Order by Relevance | Date
Total 21 results found since Jan 2013.
CO4 Outcomes of Non –Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Diabetes Mellitus: A Systematic Review of Randomized Controlled Trials and Observational Studies
This study aimed to ident ify differences between original studies of NOACs vs warfarin to support interpretation of results across studies.
Source: Value in Health - June 1, 2023 Category: International Medicine & Public Health Authors: R. Wang, H. Lien, A. Borrow, D. Fleishman Source Type: research
Oral anticoagulants: a systematic overview of reviews on efficacy and safety, genotyping, self-monitoring, and stakeholder experiences
ConclusionsFor stroke prevention in AF, direct OACs seem to be more effective and safer than usual care, and apixaban (5 mg twice daily) had the best profile. For VTE, there was no strong evidence that direct OACs were better than usual care. Education and pharmacist management could improve coagulation control. Both clinicians and patients rated efficacy and safety as the most important factors in managing AF and V TE.Systematic review registrationPROSPERO CRD42017084263 —one deviation; efficacy and safety were from one review.
Source: Systematic Reviews - October 28, 2022 Category: International Medicine & Public Health Source Type: research
EE411 Healthcare Costs of Direct Oral Anticoagulants Among Medicare Patients with Nonvalvular Atrial Fibrillation and Multimorbidity
To evaluate cost differences between stroke/systemic embolism (S/SE) and major bleeding (MB) among nonvalvular atrial fibrillation (NVAF) patients with multimorbidity prescribed direct oral anticoagulants (DOACs) or warfarin.
Source: Value in Health - June 26, 2022 Category: International Medicine & Public Health Authors: AD Dhamane, M Ferri, A Keshishian, C Russ, N Atreja, R Thomas, G Leung, B Emir, H Yuce, M DiFusco Source Type: research
Secondary analysis confirms safety of blood thinning agent
(American Heart Association) The blood thinner apixaban, which treats and prevents blood clots in some people with irregular heart rhythm, is safe and effective in stroke patients. Apixaban is associated with less bleeding, death and hospitalization than warfarin.
Source: EurekAlert! - Medicine and Health - February 21, 2020 Category: International Medicine & Public Health Source Type: news
Optimal Choice of Pharmacological Therapy – Prevention of Stroke and Assessment of Bleeding Risk in Patients with Atrial Fibrillation
Conclusions:Novel oral anticoagulants (NOACs) seem to be a better choice as a pharmacological therapy in the treatment of AF, due to a lack of adequate monitoring of patients ’ international normalized ratio (INR) values. CHA2DS2‑VASc and HASBLED scores must be used as a part of routine clinical diagnostics when dealing with patients with AF.Keywords:Atrial fbrillation, hemorrhage, risk, stroke, therapeutics
Source: International Journal of Preventive Medicine - June 3, 2019 Category: International Medicine & Public Health Source Type: research
Cost-Utility Analysis of Apixaban versus Warfarin in Atrial Fibrillation Patients with Chronic Kidney Disease
Warfarin use for stroke prevention in atrial fibrillation (AF) patients with chronic kidney disease is debated. Apixaban was shown to be safer than warfarin, with superior reduction in the risk of stroke, systemic embolism, mortality, and major bleeding irrespective of kidney function.
Source: Value in Health - July 24, 2018 Category: International Medicine & Public Health Authors: Shoroq M. Altawalbeh, Osama Y. Alshogran, Kenneth J. Smith Source Type: research
Perceived Advantages and Disadvantages of Oral Anticoagulants, and the Trade-offs Patients Make in Choosing Anticoagulant Therapy and Adhering to Their Drug Regimen
Oral anticoagulant therapy (OAT) is proven to be highly effective for stroke prevention in patients suffering from atrial fibrillation (AF) [1,2]. Vitamin K antagonists (VKAs), particularly warfarin, which is the most commonly used VKA, have long been the standard of care to prevent AF-related stroke [3]. However, in recent years the European Medicines Agency has approved a number of direct oral anticoagulants (DOACs) as (possible) alternatives to VKAs. The perceived benefits of DOACs include their high efficacy and low risk of bleeding, the rapid onset/offset of action, fewer food and drug interactions, and predictable ph...
Source: Patient Education and Counseling - July 2, 2018 Category: International Medicine & Public Health Authors: Melissa C.W. Vaanholt, Marieke G.M. Weernink, Clemens von Birgelen, Catharina G.M. Groothuis-Oudshoorn, Maarten J. Ijzerman, Janine A. van Til Source Type: research
Apixaban is a safe alternative to warfarin during catheter ablation of atrial fibrillation
(European Society of Cardiology) Apixaban and warfarin are equally safe during catheter ablation of atrial fibrillation, according to results of the AXAFA-AFNET 5 trial presented today in a late-breaking trial session at EHRA 2018, a European Society of Cardiology (ESC) congress.1 There were similar rates of stroke and bleeding, and an improvement in cognitive function was shown for the first time.
Source: EurekAlert! - Medicine and Health - March 20, 2018 Category: International Medicine & Public Health Source Type: news
Cost-Effectiveness of Edoxaban In Patients With Non-Valvular Atrial Fibrillation In Hong Kong
Atrial fibrillation (AF) is a common arrhythmia associated with debilitating consequences such as stroke, heart failure and venous thromboembolism. In HK, 20-25% of stroke cases are related to AF leading to a significant burden. Warfarin has been the frontline oral anticoagulant for AF but with high bleeding risk and hence monitoring and dose adjustment are required. The non-vitamin-K antagonist oral anticoagulants (NOACs) are alternatives to warfarin for preventing stroke and systemic embolism in non-valvular AF (NVAF) patients.
Source: Value in Health - October 1, 2017 Category: International Medicine & Public Health Authors: DB Wu, WY Choon, KK Lee Source Type: research
Apixaban lowers stroke risk in AF patients undergoing cardioversion (EMANATE)
(European Society of Cardiology) Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-na ï ve patients with atrial fibrillation scheduled for elective cardioversion, according to late-breaking results from the EMANATE trial presented today in a Hot Line LBCT Session at ESC Congress. Rates of bleeding were similar between the two groups.
Source: EurekAlert! - Medicine and Health - August 28, 2017 Category: International Medicine & Public Health Source Type: news
Dabigatran superior to warfarin when anticoagulation is resumed after bleeding
(University of Pittsburgh Schools of the Health Sciences) In the first analysis of how to treat patients on anticoagulants who suffer a major bleeding event, a clinical practice that routinely gives doctors pause, while also evaluating a new drug, University of Pittsburgh researchers aim to provide much-needed guidance to clinicians trying to balance the risks of stroke versus bleeding when determining the best treatment.
Source: EurekAlert! - Social and Behavioral Science - December 1, 2016 Category: Global & Universal Source Type: news
New oral anticoagulants provide same stroke prevention as warfarin but cause less bleeding
(European Society of Cardiology) The new oral anticoagulants provide the same stroke prevention as warfarin but cause less intracranial bleeding, reports an observational study in more than 43,000 patients presented at ESC Congress 2016 today by Dr. Laila Staerk, a research fellow at Herlev and Gentofte University Hospital, Denmark.
Source: EurekAlert! - Medicine and Health - August 27, 2016 Category: Global & Universal Source Type: news
PM176 Effect of Mitral Regurgitation in Non-Rheumatic Atrial Fibrillation Patients Taking and not Taking Warfarin on Stroke and Bleeding
Atrial fibrillation (AF) increases risk of stroke significantly. Prevention of this complication by using anticoagulant is recommended when the benefits outweigh the risks. Many AF patients also have mitral regurgitation (MR) as co-morbidity. However, there is lack of data describing the relationship between the bleeding risk and expected benefit from using anticoagulant in this kind of patients.
Source: CVD Prevention and Control - May 31, 2016 Category: Global & Universal Authors: Y. Vorasettakarnkij, K. Chintanavilas Tags: Poster Abstract Source Type: research
Cost Effectiveness of Apixaban (Novel Oral Anti-Coagulant) Compared with Conventional Therapy for Stroke Prophylaxis among Renal Impaired Patients with Atrial-Fibrillation from Perspective of Us Third Party Payer
Atrial Fibrillation (AF) has been a major risk factor for the development of stroke making anticoagulation therapy necessary. While on prophylaxis treatment, renal impaired patients on conventional anticoagulation (Warfarin) are at an increased risk for major bleeding. Apixaban has been shown to have better safety profile than Warfarin in face to face clinical trial. However, no study were found to have compared the cost effectiveness of Apixaban with Warfarin among renal impaired patients. We attempted to estimate the short term (one year) cost effectiveness of Apixaban compared to Warfarin for stroke prophylaxis among re...
Source: Value in Health - April 30, 2016 Category: Global & Universal Authors: A Kumar, W Wu, M Nili Source Type: research
Relationship of Time in Therapeutic Range (Ttr) with Bleeding and Stroke Incidences of Warfarinised Patients with Pulmonary Embolism in a Tertiary Hospital in Malaysia
This study aims to compare time in therapeutic range (TTR) of warfarin in patients with pulmonary embolism with bleeding and stroke and determine reasons of INR falling out of range.
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: N Sudirman, S Shaharuddin, CM Long, R Hashim, HH Zulkifly, SS Kasim, CW Lim Source Type: research
